Business
Authority for allotment of New Shares
Allergy Therapeutics plc is considering an equity raise to facilitate a potential dual listing on the Hong Kong Stock Exchange, expected in the first half of 2026. To enable this, the company is seeking shareholder approval at a general meeting on December 29, 2025, to allot up to 610,000,000 new ordinary shares, representing approximately 10% of current issued share capital, and to disapply pre-emption rights. Funds raised would support the development of allergy treatments and general corporate purposes, including working capital needs prior to the Hong Kong listing. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nAuthority for allotment of up to 610,000,000 New Shares and disapplication of pre-emption rights to facilitate a Potential Equity Raise\n \nNotice of General Meeting to be held on 29 December 2025\n \n \n12 December 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that the Board is considering potentially undertaking an equity raise which would be structured by issuing New Shares to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the \"Potential Equity Raise\").\n \nThe Potential Equity Raise would be carried out ahead of the potential dual listing of the Company's shares on the Hong Kong Stock Exchange, which was announced on 6 November 2025 and which is expected to occur in the first half of 2026 (the \"Hong Kong Listing\").\n \nIn order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board is seeking specific shareholder approval at a general meeting (the \"General Meeting\") for the allotment and issue of up to 610,000,000 ordinary shares of £0.001 each (\"New Shares\") (which is approximately 10% of the Company's current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine.\n \nIn order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board wishes to seek separate authorities to dis-apply pre-emption rights in respect of the allotment of the New Shares pursuant to the Potential Equity Raise.\n \nThe General Meeting will be held at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4BQ, United Kingdom at 11:00 a.m. (UK time) on 29 December 2025.\n \nAt this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price of any Potential Equity Raise have not been agreed. To the extent that any money is raised from the Potential Equity Raise, it would be applied towards ...